Dojolvi (triheptanoin)

Context: LC-FAOD; diet-managed metabolic condition with specialist oversight.

Evidence: $6.4M (2020) → $88.0M (2024).

Role Innovation Lab Founder and Leader (~54-person team); Rarify Platform Lead; support for global pivotal Phase III Dojolvi program, including patient–site collaboration and diet-linked monitoring.